Back to Journals » ClinicoEconomics and Outcomes Research » Volume 2

Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years

Authors Degli Esposti L, Saragoni S, Batacchi P, Geppetti P, Buda S, Esposti ED

Published 28 July 2010 Volume 2010:2 Pages 113—120

DOI https://doi.org/10.2147/CEOR.S11933

Review by Single-blind

Peer reviewer comments 3

Luca Degli Esposti1, Stefania Saragoni1, Paolo Batacchi2, Pierangelo Geppetti3, Stefano Buda1, Ezio Degli Esposti4

1CliCon S.r.l., Health, Economics and Outcomes Research, Ravenna; 2Pharmaceutical Policy Department, Local Health Unit of Florence; 3Department of Preclinical and Clinical Pharmacology, University of Florence; 4Outcomes Research Unit, Policlinics Umberto I, Rome, Italy.

Objective: To perform a time-trend analysis of adherence and cost of antihypertensive ­treatment over four years.

Methods: A population-based retrospective cohort study was conducted. We included subjects ≥18 years, and newly treated for hypertension with diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers between 01 January 2004 and 31 December 2007. One-year adherence to antihypertensive therapy was calculated and classified as low, low-intermediate, intermediate, high-intermediate, and high. The direct cost of antihypertensive medications was evaluated.

Results: We included data for a total of 105,512 patients. The number of newly treated subjects decreased from 27,334 in 2004 to 23,812 in 2007, as well as antihypertensive drug therapy cost which decreased from €2,654,166 in 2004 to €2,343,221 in 2007. On the other hand, in the same time frame, the percentage of adherent newly treated subjects increased from 22.9% to 28.0%. Compared with subjects initiated on angiotensin receptor blockers (odds ratio [OR] = 1), the risk of nonadherence was higher in those initiated on angiotensin-converting enzyme inhibitors (OR = 1.19), combination therapy (OR = 1.44), beta-blockers (OR = 1.56), calcium channel blockers (OR = 1.67), and diuretics (OR = 4.28).

Conclusions: The findings of the present study indicate that suboptimal adherence to antihypertensive medication occurs in a substantial proportion of treated patients, and improvements in treatment adherence were obtained but are still unsatisfactory.

Keywords: antihypertensive therapy, adherence, cost, administrative databases.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]